Stellungnahme zur Nutzenbewertung von Atezolizumab (neues Anwendungsgebiet: hepatozelluläres Karzinom, Kombination mit Bevacizumab)

• Literatur

• 1 Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert Koch-Institut: Krebs in Deutschland 2011/2012, Häufigkeiten und Trends: 10. Ausgabe. 2015 http://www.gekid.de/Atlas/CurrentVersion/atlas.html
• 2 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30
• 3 AWMF S3-Leitlinie H Diagnostik und Therapie des hepatozellulären Karzinoms, Mai 2013. https://www.awmf.org/uploads/tx_szleitlinien/032-053OLl
• 4 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
• 5 Kudo M, Finn RS, Qin S. et al. A Randomised Phase 3 trial of lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. Lancet 2018; 391: 1163-1173
• 6 Yau T, Park JW, Finn RS. et al CheckMate 459: a randomized, multicenter phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as firstline (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019; 30 (Suppl. 05) v874v875 (abstract), https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/CheckMate-459-A-Randomized-Multi-Center-Phase-3-Study-of-Nivolumab-NIVO-vs-Sorafenib-SOR-as-First-Line-1L-Treatment-in-Patients-pts-With-Advanced-Hepatocellular-Carcinoma-aHCC
• 7 Finn RS, Ryoo BY, Merle P. et al. Pembrolizumab as second line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE240: a randomized, double blind, phase III trial. J Clin Oncol 2020; 38: 193-202
• 8 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905
• 9 Finn RS, Qin S, Ikeda M. et al. IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma. ASCO GI Cancer, Abstract 267. 2021
• 10 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
• 11 Cherny NI, Dafni U, Bogaerts J. et al. ESMO-Magnitude of Clinical Benefit Scale version1.1. Ann Oncol 2017; 28: 2340-2366